Posted by Michael Wonder on 21 Aug 2019
NICE’s fast-track catapults Skyrizi into market
21 August 2019 - Watchdog also gives direction on comparing rival treatments.
NICE has published a final recommendation for AbbVie and Boehringer Ingelheim’s Skyrizi today, completing a fast-track process which will see the new psoriasis treatment gain market access in record time.
The drug is one of the first treatments to go through NICE’s fast-track appraisal system, which accelerates the review process and also cuts the standard 90 day implementation period down to 30 days.
